3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
39
Lymphoma, B-Cell, Marginal Zone
22
Lymphoma, Mantle-Cell
19
Lymphoma, Follicular
18
Lymphoma
17
Lymphoma, Non-Hodgkin
15
Leukemia, Lymphocytic, Chronic, B-Cell
12
Lymphoma, B-Cell
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Recurrence
8
Burkitt Lymphoma
8
Waldenstrom Macroglobulinemia
7
Neoplasms
6
Leukemia, Hairy Cell
4
Leukemia, B-Cell
3
Leukemia
3
Hematologic Neoplasms
3
beta-Thalassemia
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm, Residual
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Heart Failure
2
Epstein-Barr Virus Infections
2
Dendritic Cell Sarcoma, Interdigitating
2
Blastic Plasmacytoid Dendritic Cell Neoplasm
2
Anemia, Refractory, with Excess of Blasts
2
Thalassemia
1
Sjogren's Syndrome
1
Interventions
ofatumumab
1
daratumumab
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
×
Rituximab
×
Clear all
NCT03274375
2023-07-13
IANMDAR
Assistance Publique - Hôpitaux de Paris
Phase 2
Recruiting
20 enrolled